If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
Description
The polyclonal antibody reacts with the second extracellular domain of human junction adhesion molecule (JAM)-A (also known as JAM, JAM-1 or F11R). Together with JAM-C (JAM-2) and JAM-B (VE-JAM or JAM-3), JAM-A belongs to a family of adhesion proteins with a V-C2 immunoglobulin domain organization. JAMs are important for a variety of cellular processes, including tight junction assembly, leukocyte transmigration, platelet activation, angiogenesis and virus binding. JAM-A is expressed by endothelial and epithelial cells, platelets, neutrophils, monocytes, lymphocytes and erythrocytes. Like all other JAMs, JAM-A play an important role in tight junctions where it is involved in cell-to-cell adhesion through homophilic interaction. It codistributes with other tight junction components as ZO-1, 7H6 antigen, cingulin and occludin. JAM-A also plays an important role in leukocyte transmigration. Leukocyte transmigration can be blocked by antibodies and by soluble JAM-A/Fc fusion proteins. Homophilic JAM-A interactions between leukocytes and the endothelium but also heterophilic interactions of JAM-A with the b2-integrin leukocyte function-associated antigen-1 (LFA-1) are considered to actively guide leukocytes during transmigration. Several studies imply a role of JAM-A in the initiation of atherosclerosis, since JAM-A is upregulated on early atherosclerotic endothelium and adhesion of activated platelets on activated endothelium is mediated by homophilic interactions of JAM-A. The polyclonal antibody reacts with the 17 kDa extracellular domain 2 of the human JAM-A protein. The immunogen used for rabbit immunization is the extracellular domain of full-length human JAM-A. The antibody does not react with mouse JAM-A.